Ram Kumar Sahu, - and Mounir M Salem-Bekhit, - and Bedanta Bhattacharjee, - and Yosif Almoshari, - and Abu Md Ashif Ikbal, - and Meshal Alshamrani, - and Alakesh Bharali, - and Ahmad Salawi, - and Retno Widyowati, - and Abdulrahman Alshammari, - and Ibrahim Elbagory, - (2023) Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics, 10 (9). pp. 1-22. ISSN 2079-6382

	Text (FULLTEXT) C-25_artikel.pdf Download (9MB)
	Text (Kualitas Karil) Kualitas Karil C-25.pdf Download (485kB)
	Text (Similarity) C-25_similarity.pdf Download (6MB)

Abstract

Mucormycosis in patients who have COVID-19 or who are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating and fatal, leading to loss of organs and emotional trauma. Radiographic manifestations are not specific, but diagnosis can be made through microscopic examination of materials collected from necrotic lesions. Treatment requires multidisciplinary expertise, as the fungus enters through the eyes and nose and may even reach the brain. Use of the many antifungal drugs available is limited by considerations of resistance and toxicity, but nanoparticles can overcome such limitations by reducing toxicity and increasing bioavailability. The lipid formulation of amphotericin-B (liposomal Am-B) is the first-line treatment for mucormycosis in COVID-19 patients, but its high cost and low availability have prompted a shift toward surgery, so that surgical debridement to remove all necrotic lesions remains the hallmark of effective treatment of mucormycosis in COVID-19. This review highlights the pathogenesis, clinical manifestation, and management of mucormycosis in patients who have COVID-19.

Actions (login required)

View Item